Erschienen in:
28.08.2020 | ASO Author Reflections
ASO Author Reflections: Undertreatment of Pancreatic Cancer After Resection: Don’t Get Fooled by Favorable Final Pathology
verfasst von:
Elizabeth Olecki, MD, Niraj Gusani, MD, MS, FACS, Chan Shen, PhD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 3/2021
Einloggen, um Zugang zu erhalten
Excerpt
Landmark trials, including CONKO-1
1 and ESPAC-1
2, have established that adjuvant chemotherapy in surgically resected pancreatic cancer leads to improved overall survival. Despite evidence from trials and guideline recommendations for both surgical resection and chemotherapy in all early-stage pancreatic cancers, undertreatment, in the form of omission of chemotherapy, has been found to be as high at 60% in those who have undergone resection.
3 Demographic and socioeconomic factors have previously been identified to be associated with undertreatment. However, tumor biology, long considered the ‘king’ of all factors affecting outcomes in surgical oncology,
4 has not previously been evaluated as a potential factor associated with undertreatment in pancreatic cancer. …